Skip to content

COMPARATIVE CLINICAL STUDY OF PADASEKA AND PADABHYANGA WITH KUSHADYA TAILA IN MADHUMEHAJA PADA DAHA WITH SPECIAL REFERENCE TO DIABETIC PERIPHERAL NEUROPATHY

TO EVALUVATE THE EFFECT OF PADASEKA AND PADABHYANGA WITH KUSHADYA TAILA IN MADHUMEHAJA PADA DAHA WITH SPECIAL REFERENCE TO DIABETIC PERIPHERAL NEUROPATHY-A RAMDOMISED COMPARATIVE CLINICAL STUDY - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062825
Enrollment
40
Registered
2024-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E08-E13- Diabetes mellitus

Interventions

None listed

Sponsors

DR MALLIKARJUN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with either sex between the age group of 30-70 yrs with diagnosed diabetic mellitus presenting with pada daha. 2. Patients fit for padaseka 3. Patients fit for padabhyanga

Exclusion criteria

Exclusion criteria: 1. Patients with any other systemic disorders which may interfere with the course of treatment will be excluded. 2. Trauma, infectious wounds, gangrene, non-healing ulcer of foot, Mononeuropathies. 3. Neuropathies Secondary to causes other than Diabetes.

Design outcomes

Primary

MeasureTime frame
Changes in pada daha, tingling sensation, pain with kushyadi taila padabhyanga.Timepoint: OTH DAY BEFORE TREATMENT,14TH DAY AFTER TREATMENT AND FOLLOW UP DONE ON 21ST DAY AND 30TH DAY.

Secondary

MeasureTime frame
Changes in pada daha, tingling sensation, pain with kushyadi taila pada sekaTimepoint: 14TH DAY AFTER TRAEMENT FOLLOW UP ON 21ST DAY AND 30TH DAY

Countries

India

Contacts

Public ContactDR MAHALAKSHMI K M

DHANVANTARI AYURVEDA COLLEGE HOSPITAL AND RESEARCH CENTRE, SIDDAPUR UTTARA KANNADA

drmahalakshmi15@gmail.com9900979629

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026